Determine Risk of Cognitive Impairments

Personalized Genetic Testing provides an invaluable service to physicians and patients throughout the U.S.

Thousands of Tests Performed

Providing doctors with the information needed to determine the best medicines and treatments for each of their patients.

20+ Years Experience

Experience in biotechnology, pharmaceutical, hematology, flow cytometry, clinical molecular biology, immunology, and chemistry industries.

Fast 5-Day Turnaround

Using the latest technologies from the leaders in the industry, our process is 3 times faster than competitor’s analysis methods.

Accurate Reporting

Through Coriell Institute, backed by over 60 years of research experience providing the quality control required for validation in pharmacogenetics testing.

PGT’s COMT Gene Testing supports doctors in determining the risk factors associated with cognitive impairments based on a patient’s genetic profile.

Catechol-O-Methyltransferase (COMT) Genotyping

COMT is an enzyme that degrades dopamine and norepinephrine, primarily in the prefrontal cortex of the brain. COMT lab testing has found a common single nucleotide polymorphism (SNP) 472G>A, also referred to by the amino acid change 158 Val>Met, is associated with altered COMT enzymatic activity. The 158 Met allele has lower enzymatic activity resulting in less dopamine degradation and higher dopamine concentrations as compared to those carrying the Val allele. Conversely, the 158 Val allele has higher activity and results in lower dopamine levels in the prefrontal cortex. Low dopamine concentrations are associated with cognitive impairments including working memory deficits. Val/Val homozygotes with depression are less likely to achieve remission when treated with SSRI antidepressants, and Val/Val homozygotes with schizophrenia are less likely to demonstrate improved cognitive effects when treated with antipsychotics. In contrast, the Met/Met homozygotes are more likely to achieve remission and demonstrate cognitive improvement when treated with SSRIs and antipsychotics, respectively. The frequency of the 158 Met variant varies from 2543% depending on the population studied.